FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 01/2022”.

The Monitor is a month-to-month revealed overview of enterprise capital developments within the US-Biotech sector.

As of the top of January 2022, we determine the next present VC developments within the US-Biotech sector:

  • Whole financing quantity for biotech firms within the US because the starting of the 12 months quantities to USD 5,324m
  • The highest 5 offers already surpassed USD 100m every within the first month of the 12 months
  • The biggest deal quantity amounted to USD 3,000m for Altos Labs
  • Surveyor Capital dominates the highest 5 traders by deal measurement (USD 61m), adopted by Foresite Capital Administration (USD 60m) and Normal Catalyst (USD 46m)
  • Central nervous system is the indication with the very best funding exercise at the start of the 12 months

To entry the total report, please click on right here.

By Dr. Mathias Schott and Sebastian Sommer

Leave a Reply

Your email address will not be published.